Merz Aesthetics has made an investment in Acorn Biolabs by leading its Series A funding round. Acorn Biolabs is a personalized regenerative medicine company with offices in Toronto, Canada and Los Angeles, U.S. Acorn Biolabs offers the world’s first non-invasive, follicle-based, stem cell cryopreservation service and is developing treatments made from a client’s own cells. Terms were not disclosed. “Merz Aesthetics is at the forefront of the emerging field of regenerative aesthetics, which seeks to stimulate the body’s own systems to repair and restore the structure and integrity of aging skin," says Jon Parrish, PhD, chief corporate development officer at Merz Aesthetics. "We are looking to invest in opportunities that lie at the intersection of regenerative aesthetics and personalized medicine and our investment in Acorn Biolabs directly aligns with this strategy.”
Acorn Biolabs offers a non-invasive way to preserve stem cells for future regenerative treatments, including both therapeutic and aesthetic applications. Acorn Biolabs currently has partner clinics across the U.S. and Canada offering their cell cryopreservation service and are preparing to launch their first cell-based application, a topical aesthetic product, in Q2 2024. “This funding enables us to expand our commercial operations in Canada and the U.S., and to continue research and development of regenerative aesthetic applications,” says Drew Taylor, MSc, PhD, and CEO of Acorn Biolabs. “We look forward to collaborating with the Merz Aesthetics teams, leveraging their commercial and development expertise in aesthetics.”